Subcutaneous administration of ADAMTS13
AssigneeTakeda Pharmaceutical Company Limited
InventorsAlexandra Nathalie Kopic, Werner Hoellriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
Life of this patent
Estimating the term…
Abstract
This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
Claims17
A method for treating a condition selected from the group consisting of inherited TTP, acquired TTP, cerebral infarction, myocardial infarction, ischemic/reperfusion injury, deep vein thrombosis, and sepsis-related disseminated intravascular coagulation in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated a disintegrin and metalloproteinase with thrombospondin type I motifs 13 (ADAMTS13) to the mammal in need thereof, wherein bioavailability of the ADAMTS13 after subcutaneous administration is at least 40% as compared to intravenous administration normalized for the same dose, thereby treating said condition in said mammal.
A method for treating a bleeding episode associated with an increase in blood clotting activity associated with a condition selected from the group consisting of inherited TTP, acquired TTP, cerebral infarction, myocardial infarction, ischemic/reperfusion injury, deep vein thrombosis, and sepsis-related disseminated intravascular coagulation in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated a disintegrin and metalloproteinase with thrombospondin type I motifs 13 (ADAMTS13) to the mammal in need thereof, wherein the ADAMTS13 has a bioavailability of at least 40% after subcutaneous administration as compared to intravenous administration normalized for the same dose, thereby treating said condition in said mammal.
Dependencies are inferred from the claim text.